Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 14Lymphoid 6Genitourinary 5Other hematologic neoplasm 3Gastrointestinal 2Thoracic 1Other solid neoplasm 1Myeloid 1Head & Neck 1Gynecologic 1Classical hematology 1

Conditions

Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms by Histologic Type 1Lung Neoplasms 1Head and Neck Neoplasms 1Colorectal Neoplasms 1

Interventions

Paclitaxel 575Carboplatin 521Cisplatin 351Bevacizumab 252pembrolizumab 228Gemcitabine 157Topotecan 128Cyclophosphamide 128liposomal doxorubicin 127olaparib 120Taxes 113Radiotherapy 110Docetaxel 94Brachytherapy 89Doxorubicin 84Drug Therapy 81niraparib 75Nivolumab 71Magnetic Resonance Spectroscopy 71Specimen Handling 65fludarabine 57Biopsy 55Hyperthermic Intraperitoneal Chemotherapy 53Filgrastim 52Letrozole 50Oxaliplatin 48durvalumab 47Immunoglobulin G 47atezolizumab 46Platinum 44

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × siltuximab × Gynecologic × Clear all
NCT00841191 2014-05-14

A Safety, Efficacy and Pharmacokinetic Study of Siltuximab (CNTO 328) in Participants With Solid Tumors

Centocor, Inc.

Phase 1/2 Completed
84 enrolled
GastrointestinalGynecologicHead & NeckThoracic

Head and Neck Neoplasms, Lung Neoplasms, Neoplasms by Histologic Type, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡